Evidence map›Paper›PMID 28288952›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.

Aaron T Gerds, Kwang Woo Ahn, Zhen-Huan Hu, Hisham Abdel-Azim, Gorgun Akpek, Mahmoud Aljurf, Karen K Ballen, Amer Beitinjaneh, Ulrike Bacher, Jean-Yves Cahn and 26 more

Open access · hybridAbstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Existing agents, novel agents, or transplantation for high-risk MDS.Hematology. American Society of Hematology. Education Program · 2020
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.Hematology. American Society of Hematology. Education Program · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 8 countries.

Aaron T GerdsHematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: gerdsa@ccf.org.
Kwang Woo AhnCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
Zhen-Huan HuCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Hisham Abdel-AzimDivision of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
Gorgun AkpekStem Cell Transplantation and Cell Therapy, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Karen K BallenDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Amer BeitinjanehDivision of Hematology and Oncology, University of Miami, Miami, Florida.
Ulrike BacherDepartment of Hematology, Inselspital Bern, Bern, Switzerland; Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany.
Jean-Yves CahnDepartment of Hematology, University Hospital, Grenoble, France.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Corey CutlerCenter for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Andrew DalyTom Baker Cancer Center, Calgary, Alberta, Canada.
Zachariah DeFilippDepartment of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Robert Peter GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
Usama GergisHematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
Michael R GrunwaldLevine Cancer Institute, Charlotte, North Carolina.
Gregory A HaleDepartment of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Betty Ky HamiltonBlood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
Madan JagasiaDivision of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
Tamila Kindwall-KellerDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.
Taiga NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Richard F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Muthalagu RamanathanDivision of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts.
Ayman A SaadDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Melhem SolhThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.
Celalettin UstunDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota.
David ValcárcelDepartment of Hematology, Hospital Vall d'Hebron, Barcelona, Spain.
Erica WarlickDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota.
Baldeep M WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.
Matt KalaycioHematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Edwin AlyeaCenter for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Uday PopatM.D. Anderson Cancer Center, Houston, Texas.
Ronald SobecksHematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Cleveland Clinic · USMedical College of Wisconsin · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USUniversity of Minnesota Medical Center · USBaylor College of Medicine · USImperial College London · GBJohns Hopkins University · USKing Faisal Specialist Hospital & Research Centre · SALevine Cancer Institute · USMoffitt Cancer Center · USNewYork–Presbyterian Hospital · USNorthside Hospital · USRush University Medical Center · USSeattle Cancer Care Alliance · USThe University of Texas MD Anderson Cancer Center · USUMass Memorial Medical Center · USUniversité Grenoble Alpes · FRUniversity Hospital of Bern · CHUniversity of Alabama at Birmingham · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor. To date, however, there have been few published series dedicated solely to describing the outcomes of adult patients with myelodysplastic syndrome (MDS) who have undergone UCBT. Between 2004 and 2013, 176 adults with MDS underwent UCBT as reported to the Center for International Blood and Marrow Transplant Research. Median age at the time of transplantation was 56 years (range, 18-73 years). The study group included 10% with very low, 23% with low, 19% with intermediate, 19% with high, and 13% with very high-risk Revised International Prognostic Scoring System (IPSS-R) scores. The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%, and the 3-year probability of chronic GVHD was 28%. The probabilities of relapse and transplantation-related mortality (TRM) at 3 years were 32% and 40%, respectively, leading to a 3-year disease-free survival (DFS) of 28% and an overall survival (OS) of 31%. In multivariate analysis, increasing IPSS-R score at the time of HCT was associated with inferior TRM (P = .0056), DFS (P = .018), and OS (P = .0082), but not with GVHD or relapse. The presence of pretransplantation comorbidities was associated with TRM (P = .001), DFS (P = .02), and OS (P = .001). Reduced-intensity conditioning was associated with increased risk of relapse (relative risk, 3.95; 95% confidence interval, 1.78-8.75; P < .001), and although a higher proportion of myeloablative UCBTs were performed in patients with high-risk disease, the effect of conditioning regimen intensity was the same regardless of IPSS-R score. For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in this population is hampered by a high rate of TRM.

Indexed as

AdolescentAdultAgedCord Blood Stem Cell TransplantationGraft vs Host DiseaseHumansMiddle AgedMyelodysplastic SyndromesProbabilityRecurrenceRisk AssessmentSurvival AnalysisTransplantation ConditioningTreatment OutcomeYoung AdultBlood and marrow transplantationMyelodysplastic syndromeUmbilical cord transplantation

Identifiers

PMID28288952
PMCPMC5474679
OpenAlexW2591670358

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.